BioCryst is profitable. Now it wants to buy more rare disease drugs
CNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our journalism to elevate stories that advance research, innovation and patient care in rare diseases. The science behind rare disease drug development is changing fast, and with it, so is the financial engine that drives it all. This month saw the launch of…